SEC Form 4 · accession 0001209191-17-012753
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Charnas
Officer — See Remarks
Period of report
Feb 16, 2017
Accepted (ET)
Feb 21, 2017 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401667
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F1 | $37.35 | Feb 16, 2017 | A | 15,750 | A | — | Feb 15, 2027 | COMMON STOCK | 15,750 | 15,750 | D |
Explanation of responses
- F1The vesting commencement date ("Vesting Commencement Date") of the option is February 16, 2017. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer.
Remarks
The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer.